Recent 8-K filings for SVRA
Highest-materiality recent filing
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
- Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
- Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).
-
Savara signs lease for new HQ in Yardley, PA; 5-year term starting July 2026
Lease for 10,795 sq ft at 19 W. College Ave, Yardley, PA; term 7/1/2026 to 12/1/2031.
-
Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI
Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
-
Savara updates corporate presentation; no material new disclosures
Corporate presentation posted on IR website and furnished as exhibit.
-
Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share
23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
-
Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action
RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
-
Savara updates corporate presentation; no material new disclosures
Updated corporate presentation posted on IR website and furnished as Exhibit 99.1.
-
Savara stockholders elect directors, ratify auditors, and approve say-on-pay at 2025 annual meeting
All six director nominees elected with at least 118.7 million votes in favor each.
-
Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025
FDA requested additional CMC data; RTF not due to safety or efficacy concerns.
-
Savara terminates ATM equity offering agreement with Evercore, effective April 2, 2025
Delivered notice to Evercore on March 31, 2025 terminating the ATM Agreement under Section 12(b).
-
Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close
$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
-
Savara sets 2025 executive bonus targets; CEO bonus $330k, other execs $165k-$200k
CEO Matthew Pauls target bonus $330,000 (50% of base salary).
-
Savara updates corporate presentation; no material new information disclosed
Corporate presentation updated and posted on IR website on January 13, 2025.
-
Savara prices $100M common stock offering at $3.81/sh, 26.2M shares
Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.
-
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
-
Savara stockholders approve 2024 Omnibus Incentive Plan adding 11.7M new shares
Stockholders approved 2024 Omnibus Incentive Plan at June 6, 2024 annual meeting.
-
Savara shareholders approve officer exculpation charter amendment and 2024 omnibus incentive plan
Amendment to certificate of incorporation allowing officer exculpation under Delaware law approved (88.6M for, 14.1M against).
Materiality & sentiment trend
Max materiality 0.90 · Median 0.40 · Most common event other_material